Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand.

Ardelyx Inc. (NASDAQ:ARDX) jumped 2.42 (71%) to $5.24 Tuesday on AMPLIFY's

Read the full 426 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE